JanOne to Present In Person and by Video at H.C. Wainwright's 25th Annual Global Investment Conference
LAS VEGAS, Aug. 31, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), the biopharmaceutical company focused on developing non-addicting painkillers and novel treatments for the causes of pain, will participate in investor sessions at the H.C. Wainwright 25th Annual Global Investment Conference in New York City. JanOne's Chief Medical Officer, Dr. Amol Soin, will appear via recorded video and attend the conference in person to represent the company's mission and progress.
- LAS VEGAS, Aug. 31, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), the biopharmaceutical company focused on developing non-addicting painkillers and novel treatments for the causes of pain, will participate in investor sessions at the H.C. Wainwright 25th Annual Global Investment Conference in New York City.
- JanOne's Chief Medical Officer, Dr. Amol Soin, will appear via recorded video and attend the conference in person to represent the company's mission and progress.
- Dr. Soin's virtual presentation will be shown September 11 — 13th and will be accessible on the JanOne.com website in subsequent days.
- This week, on August 29, JanOne announced that it had received a US Patent for its use of its novel formulation of low-dose naltrexone, Jan123, to treat chronic pain.